BVS Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -3.47% compared to Bioventus's net margin of --. Bioventus's return on equity of -18.97% beat Perspective Therapeutics's return on equity of --.

Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.45%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than Bioventus, analysts believe Perspective Therapeutics is more attractive than Bioventus.

Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Bioventus quarterly revenues are $139M, which are larger than Perspective Therapeutics quarterly revenues of --. Bioventus's net income of -$4.8M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Bioventus's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -3.47% compared to Bioventus's net margin of 14.25%. Bioventus's return on equity of -18.97% beat Insulet's return on equity of 49.55%.

Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.45%. On the other hand Insulet has an analysts' consensus of $285.63 which suggests that it could grow by 8.51%. Given that Bioventus has higher upside potential than Insulet, analysts believe Bioventus is more attractive than Insulet.

Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.859%.

Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Bioventus quarterly revenues are $139M, which are smaller than Insulet quarterly revenues of $543.9M. Bioventus's net income of -$4.8M is lower than Insulet's net income of $77.5M. Notably, Bioventus's price-to-earnings ratio is -- while Insulet's PE ratio is 45.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 10.14x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -3.47% compared to Bioventus's net margin of -4291.67%. Bioventus's return on equity of -18.97% beat Catheter Precision's return on equity of -65.84%.

Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.45%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than Bioventus, analysts believe Catheter Precision is more attractive than Bioventus.

Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Bioventus quarterly revenues are $139M, which are larger than Catheter Precision quarterly revenues of $96K. Bioventus's net income of -$4.8M is lower than Catheter Precision's net income of -$4.1M. Notably, Bioventus's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -3.47% compared to Bioventus's net margin of -17.98%. Bioventus's return on equity of -18.97% beat Xtant Medical Holdings's return on equity of -35.98%.

Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.45%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Bioventus, analysts believe Xtant Medical Holdings is more attractive than Bioventus.

Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Bioventus quarterly revenues are $139M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Bioventus's net income of -$4.8M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Bioventus's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.